期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 97, 期 -, 页码 101-110出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2015.11.014
关键词
Fibronectin; Drug target; Blood vessels; Tumor; Cancer; Imaging; Vaccination
资金
- Canadian Institutes of Health Research [MOP-106494]
- Canada Research Chair program
- Quebec Network of Oral and Bone Health Research
- Natural Sciences and Engineering Research Council of Canada [RGPIN-2015-04891]
- Fonds de recherche du Quebec - Nature et technologies
Fibronectin is an extracellular matrix protein with pivotal physiological and pathological functions in development and adulthood. Alternative splicing of the precursor mRNA, produced from the single copy fibronectin gene, occurs at three sites coding for the EDA, EDB and IIICS domains. Fibronectin isoforms comprising the EDA or EDB domains are known as oncofetal forms due to their developmental importance and their re-expression in tumors, contrasting with restricted presence in normal adult tissues. These isoforms are also recognized as important markers of angiogenesis, a crucial physiological process in development and required by tumor cells in cancer progression. Attributed to this feature, EDA and EDB domains have been extensively used for the targeted delivery of cytokines, cytotoxic agents, chemotherapy drugs and radioisotopes to fibronectin-expressing tumors to exert therapeutic effects on primary cancers and metastatic lesions. In addition to drug delivery, the EDA and EDB domains of fibronectin have also been utilized to develop imaging strategies for tumor tissues. Furthermore, EDA and EDB based vaccines seem to be promising for the treatment and prevention of certain cancer types. In this review, we will summarize recent advances in fibronectin EDA and EDB-based therapeutic strategies developed to treat cancer. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据